- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00470509
Adalimumab in Severe and Acute Sciatica (ASAS)
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Geneva, Switzerland, 1211
- Geneva University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients older than 18
- Episode of radicular pain in one lower limb for less than 12 weeks.
- Medical evaluation requiring hospitalisation because of pain or functional handicap
Patients presenting a characteristic leg pain in the L3, L4, L5, or S1 territories plus at least one of the following: :
- positive straight-leg-raising test with an elevation of less than 70°
- positive femoral stretched
clear clinical sign of nerve root involvement
- muscle strength deficiency or
- sensory disturbances in clear cut dermatome or
- lower limb reflex asymmetry.
- Oswestry score greater than 50
- If there is a past history of radicular pain involving the same nerve root, a 6 months interval free of leg pain is required.
- A confirmed herniated disc on usual imaging techniques (CT scan or MRI) in the vicinity of the clinically involved nerve root that has been performed within the last 2 years.
- Written informed consent
Exclusion Criteria:
The presence of recent (<48 hours) severe muscle weakness (<3/5) or clinical signs of cauda equina compression, requiring immediate surgery.
- If surgical procedure is required but is denied, either because of surgeon's decision or because of patient's fully informed decision, then this patient could be included in the protocol.
Comorbidities such as :
- Coexisting infections (Chest X-ray will be performed to all patients and tuberculin skin test in case of doubt concerning a past history of tuberculous infection).
- Autoimmune disease (other than RA).
- History of cancer or malign lymphoproliferative disorders (unless the patient has been declared in remission for more than 5 years)
- History of demyelinating disorders.
- Pregnancy.
- History of intolerance to adalimumab or any of its ingredients
- Previous participation in this clinical study.
- Participation in another clinical study within 4 weeks prior to the start of or during this study.
- Poor motivation or other emotional or intellectual problems that are likely to limit the ability of the patient to comply with the protocol requirements.
- The use of cortisone prior to the inclusion IS NOT an exclusion criteria
The investigators will also be allowed to exclude an individual patient from the study and remove the blinding in case of a superimposed infection or any severe side effect during the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adalimumab
adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)
|
2 subcutaneous injections on day 0 and 7
Other Names:
|
Placebo Comparator: Placebo
2 placebo injections on day 0 and 7
|
2 subcutaneous injections on day 0 and 7
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Leg pain
Time Frame: 6 months
|
Evolution of leg pain over time.
Pain will be assessed using a Visual Analog Scale (VAS).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
delta VAS
Time Frame: 6 months
|
Percentage of amelioration for VAS and ODI (Oswestry Disability Index)
|
6 months
|
SF-12
Time Frame: 6 months
|
Assessment of patient's statisfaction and expectations using the SF12 general health questionnaire.
|
6 months
|
delta ODI
Time Frame: 6 months
|
Percentage of amelioration for ODI (Oswestry Disability Index)
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Stéphane Genevay, MD, Geneva University Hospital & Swiss Society of Rheumatology
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ASAS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sciatica
-
Prince Sattam Bin Abdulaziz UniversityCompleted
-
University Hospital, MontpellierUnknown
-
Nantes University HospitalTerminatedDiscal SciaticaFrance
-
Kyung Hee University Hospital at GangdongNational Research Foundation of KoreaUnknownChronic SciaticaKorea, Republic of
-
University of LahoreRecruitingPain | Acute SciaticaPakistan
-
Pakistan Institute of Medical SciencesRiphah International UniversityCompletedSciatica | Sciatica AcutePakistan
-
St George Hospital, AustraliaSt George & Sutherland Medical Research FoundationUnknown
-
China Medical University HospitalCompletedBack Pain | Low Back Pain | Low Back Pain, Mechanical | Low Back Pain, Recurrent | Low Back Pain, Postural | Low Back Strain | Lumbago | Lumbago With Sciatica | Lumbago With Sciatica, Unspecified SideTaiwan
-
Assistance Publique - Hôpitaux de ParisCompletedPost Operative Sciatica by Lumbar Spinal FibrosisFrance
-
Centro Universitário Augusto MottaCompletedDisability Evaluation | Manual Therapies | Physical Therapy Modalities | Sciatica Pain
Clinical Trials on Adalimumab
-
PfizerCompletedHealthyUnited States, Belgium
-
PfizerCompletedHealthy SubjectsUnited States
-
AbbottCompletedArthritis, Juvenile IdiopathicUnited States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
-
Shanghai Henlius BiotechCompleted
-
AbbottCompleted
-
Turgut İlaçları A.Ş.CompletedHealthy ParticipantsGermany
-
Mylan Inc.Mylan GmbHCompletedPsoriasis | Arthritis, PsoriaticBulgaria, Estonia, Hungary, Poland, Russian Federation, Ukraine
-
AbbottCompletedRheumatoid ArthritisSpain
-
AbbVie (prior sponsor, Abbott)CompletedRheumatoid ArthritisUnited States